Drug intelligence / Profile preview

domiphen

Development stage: Phase 2
Lead developer: Nichi-Iko Pharmaceutical
Modality: Small Molecules
Administration: Topical, Oromucosal

Overview

Domiphen is a quaternary ammonium compound primarily used as a topically administered antiseptic agent. It acts as a cationic surfactant with antimicrobial properties and is indicated for the treatment of acute infectious dental diseases and other topical infections. Domiphen exhibits potent anti-biofilm activity, disrupts microbial cell membranes, and can enhance the efficacy of other antimicrobials by inhibiting drug efflux in resistant organisms. It has also been studied for its rapid action against *Plasmodium falciparum* by interfering with energy metabolism pathways in parasites[1][2][5][6][8].

Brand names: OradolBradasolFungitex
Other names: domiphen bromide

Targets

Drug efflux pumpNeuraminidase

Beyond the preview

Go deeper on domiphen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on domiphen.

Explore the full profile